ASND vs. INCY: Ascendis Pharma vs. Incyte Stock Comparison
How do Ascendis Pharma (ASND) and Incyte (INCY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Ascendis Pharma (ASND) and Incyte (INCY) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | ASND | INCY |
|---|---|---|
| Name | Ascendis Pharma A/S | Incyte Corp. |
| Country/Region | Denmark | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 16.90 billion USD | 24.39 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | January 28, 2015 | November 4, 1993 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ASND | INCY |
|---|---|---|
| Total Return (1Y) | 29.46% | 14.06% |
| Total Return (3Y, Annualized) | 40.62% | 32.03% |
| Total Return (5Y, Annualized) | 10.03% | 12.69% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ASND | INCY |
|---|---|---|
| Volatility (1Y, Annualized) | 38.62% | 33.19% |
| Beta (5Y) | 0.38 | 0.78 |
| Max Drawdown (5Y) | -55.93% | -40.50% |
| Avg. Volume (3M) | 698.39K | 1.58M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ASND | INCY |
|---|---|---|
| Sharpe Ratio (1Y) | 0.65 | 0.29 |
| Sortino Ratio (1Y) | 0.99 | 0.46 |
Profitability
ROE (TTM)
Both companies show strong equity returns, but Ascendis Pharma (ASND) at 118.78% is the standout with ROE above its industry range; Incyte (INCY) at 7.84% also sits in the top quartile.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
118.78%
- ASND
- 118.78%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.84%
- Max
- 109.18%
- INCY
- 7.84%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Ascendis Pharma (ASND) at 70.85% keeps the most of each sales dollar — above its industry’s net margin range — and Incyte (INCY) at 6.71% also retains a top-quartile share.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
70.85%
- ASND
- 70.85%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.71%
- Max
- 18.05%
- INCY
- 6.71%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Ascendis Pharma (ASND) at 64.98% and Incyte (INCY) at 33.72% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
64.98%
- Max
- 83.12%
- ASND
- 64.98%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
33.72%
- Max
- 83.12%
- INCY
- 33.72%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ASND | INCY |
|---|---|---|
| ROE (TTM) | 118.78% | 7.84% |
| ROA (TTM) | 9.58% | 17.78% |
| Net Margin (TTM) | 70.85% | 6.71% |
| Operating Margin (TTM) | 64.98% | 33.72% |
| Gross Margin (TTM) | 91.30% | 56.02% |
Growth
Revenue Growth
Ascendis Pharma (ASND) at 98.03% sits in the top revenue growth quartile, while Incyte (INCY) at 21.22% is closer to the peer norm — faster top-line expansion for ASND.
EPS Growth
Only one side can be read here: Incyte (INCY) reports EPS growth of 4,173.33%, ranked against its industry; Ascendis Pharma (ASND) has no EPS growth figure this period.
Growth Metrics
| Metric | ASND | INCY |
|---|---|---|
| Revenue Growth (YoY) | 98.03% | 21.22% |
| Revenue Growth (3Y CAGR) | 141.43% | 14.84% |
| EPS Growth (YoY) | -- | 4,173.33% |
| EPS Growth (3Y CAGR) | -- | 61.56% |
Financial Strength
Current Ratio (MRQ)
Both Ascendis Pharma (ASND) at 2.99 and Incyte (INCY) at 3.84 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.99
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ASND
- 2.99
- Q1
- 2.47
- Min
- 0.10
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.84
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- INCY
- 3.84
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Incyte (INCY) at 0.01 keeps leverage in the lower industry quartile, while Ascendis Pharma (ASND) at 0.31 runs a more typical debt-to-equity mix.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.31
- Max
- 1.42
- Q3
- 0.65
- ASND
- 0.31
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.01
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- INCY
- 0.01
- Min
- 0.00
Financial Strength Metrics
| Metric | ASND | INCY |
|---|---|---|
| Current Ratio (MRQ) | 2.99 | 3.84 |
| Debt / Equity (MRQ) | 0.31 | 0.01 |
| Net Debt / EBITDA | -1.37 | -1.88 |
Dividends
Dividend Yield (TTM)
Neither Ascendis Pharma (ASND) nor Incyte (INCY) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ASND
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- INCY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Ascendis Pharma (ASND) nor Incyte (INCY) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ASND
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- INCY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ASND | INCY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Ascendis Pharma (ASND) at 19.68 is near its industry’s usual P/E ratio, while Incyte (INCY) at 61.05 sits in the richer quartile — INCY needs stronger growth or earnings quality to justify the premium.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.68
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- ASND
- 19.68
- Q1
- 13.30
- Min
- 0.07
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
61.05
- Max
- 85.34
- INCY
- 61.05
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Ascendis Pharma (ASND) at 16.14 and Incyte (INCY) at 4.06 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.14
- Max
- 58.18
- Q3
- 25.77
- ASND
- 16.14
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.06
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- INCY
- 4.06
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Incyte (INCY) at 4.33 is valued about in line with its industry on P/B ratio, while Ascendis Pharma (ASND) at 10.45 carries an above-peer premium to book — ASND is pricier on assets.
ASND
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.45
- Max
- 13.53
- ASND
- 10.45
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.33
- Max
- 13.53
- Q3
- 6.54
- INCY
- 4.33
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ASND | INCY |
|---|---|---|
| P/E Ratio (TTM) | 19.68 | 61.05 |
| P/S Ratio (TTM) | 16.14 | 4.06 |
| P/B Ratio (MRQ) | 10.45 | 4.33 |
| Free Cash Flow Yield (TTM) | 0.08% | 5.28% |